Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;17(3):413-21.
doi: 10.4103/2230-8210.111625.

Glucagon-like peptide-1 analogues: An overview

Vishal Gupta  1
Affiliations

Glucagon-like peptide-1 analogues: An overview

Vishal Gupta. Indian J Endocrinol Metab. 2013 May.

Abstract

Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function. Augmentation of GLP-1 results in improvement of beta cell health in a glucose-dependant manner (post-prandial hyperglycemia) and suppression of glucagon (fasting hyperglycemia), amongst other beneficial pleiotropic effects. Native GLP-1 has a very short plasma half-life and novel methods have been developed to augment its half life, such that its anti-hyperglycemic effects can be exploited. They can be broadly classified as exendin-based therapies (exenatide, exenatide once weekly), DPP-4-resistant analogues (lixisenatide, albiglutide), and analogues of human GLP-1 (liraglutide, taspoglutide). Currently, commercially available analogues are exenatide, exenatide once weekly, and liraglutide. This review aims to provide an overview of most GLP-1 analogues.

Keywords: Exenatide; GLP-analogues; glucagon-like-peptide; incretin-mimetics; incretins; liraglutide.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared

Figures

Figure 1
Figure 1
Production of GLP-1 (adapted from Holst, Jens J. The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 10 Supplement 3:14-21, August 2008)
Figure 2
Figure 2
Potential amino acid modifications that can lead to a DPP-4-resistant GLP-1 molecule analogue with prolonged half-life
See this image and copyright information in PMC

References

    1. DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95. - PMC - PubMed
    1. Deacon CF. DPPIV and diabetes. Clin Chem Lab Med. 2008;46:A18.
    1. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–65. - PubMed
    1. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. - PubMed
    1. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep. 2006;6:194–201. - PubMed